ProMIS Neurosciences Inc. — Investor Relations & Filings
Filings indexed
333
across all filing types
Latest filing
2026-02-05
Director's Dealing
Country
CA
Canada
Listing
US
PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 4 Filing | 2026-02-05 | English | |
| SCHEDULE 13G/A Filing | 2026-02-05 | English | |
| 4 Filing | 2026-02-05 | English | |
| SCHEDULE 13D/A Filing | 2026-02-05 | English | |
| 4 Filing | 2026-02-05 | English | |
| SCHEDULE 13D/A Filing | 2026-02-02 | English |
Browse filings by year
21 years- 2026 22 filings
- 2025 79 filings
- 2024 56 filings
- 2023 65 filings
- 2022 60 filings
- 2021 2 filings
- 2020 1 filing
- 2019 2 filings
- 2018 1 filing
- 2017 4 filings
- 2016 5 filings
- 2015 2 filings
- 2014 4 filings
- 2013 3 filings
- 2012 3 filings
- 2011 1 filing
- 2010 6 filings
- 2009 4 filings
- 2008 2 filings
- 2007 10 filings
- 2006 1 filing
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 29190587 | 4 Filing | 2026-02-05 | English | ||
| 29190532 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 29190521 | 4 Filing | 2026-02-05 | English | ||
| 29190498 | SCHEDULE 13D/A Filing | 2026-02-05 | English | ||
| 29190426 | 4 Filing | 2026-02-05 | English | ||
| 29190467 | SCHEDULE 13D/A Filing | 2026-02-02 | English | ||
| 29190634 | 8-K Filing | 2026-01-30 | English | ||
|
2025
8 filings
| |||||
| 12028769 | 8-K | 2025-12-16 | English | ||
| 12028766 | 8-K | 2025-11-24 | English | ||
| 12028774 | 8-K | 2025-11-19 | English | ||
| 12028768 | Major Shareholding Notification 2025 | 2025-11-15 | English | ||
| 12028767 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 12028765 | 10-Q | 2025-11-12 | English | ||
| 12028770 | 8-K | 2025-11-12 | English | ||
| 12028771 | Major Shareholding Notification 2025 | 2025-10-29 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ProMIS Neurosciences Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34916/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34916 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34916 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34916 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34916}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ProMIS Neurosciences Inc. (id: 34916)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.